Recent advances in technology now permit robust and reproducible detection of circulating tumour cells (CTCs) from a simple blood test. Standardization in methodology has been instrumental in facilitating multicentre trials with the purpose of evaluating the clinical utility of CTCs. We review the current body of evidence supporting the prognostic value of CTC enumeration in breast, prostate and colorectal cancer, using standardized approaches, and studies evaluating the correlation of CTC number with radiological outcome. The exploitation of CTCs in cancer management, however, is now extending beyond prognostication. As technologies emerge to characterize CTCs at the molecular level, biological information can be obtained in real time, with the promise of serving as a ‘surrogate tumour biopsy’. Current studies illuminate the potential of CTCs as pharmacodynamic and predictive biomarkers and potentially their use in revealing drug resistance in real time. Approaches for CTC characterization are summarized and the potential of CTCs in cancer patient management exemplified via the detection of epidermal growth factor receptor mutations from CTCs in patients with non-small cell lung cancer. The opportunity to learn more about the biology of metastasis through CTC analysis is now being realized with the horizon of CTC-guided development of novel anticancer therapies.
Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R. and Kasimir-Bauer, S. ( 2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res11: R46.
2.
Allan, A.L. and Keeney, M. ( 2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol2010: 426218.
3.
Allard, W.J., Matera, J., Miller, M.C., Repollet, M., Connelly, M.C., Rao, C. et al. (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res10: 6897-6904.
4.
Alunni-Fabbroni, M. and Sandri, M.T.(2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods50: 289-297.
5.
Ashworth, T. ( 1869) A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J14: 146-149.
6.
Attard, G., Swennenhuis, J.F., Olmos, D., Reid, A.H., Vickers, E., A’Hern, R. et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res69: 2912-2918.
7.
Budd, G.T., Cristofanilli, M., Ellis, M.J., Stopeck, A., Borden, E., Miller, M.C. et al. (2006) Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res12: 6403-6409.
8.
Christiansen, J.J. and Rajasekaran, A.K. ( 2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res66: 8319-8326.
9.
Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y. et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol26: 3213-3221.
10.
Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y. et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol20: 1223-1229.
11.
Coman, D.R., de, L.R. and MCC, U.M. ( 1951) Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli . Cancer Res11: 648-651.
12.
Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C. et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med351: 781-791.
13.
Cristofanilli, M., Hayes, D.F., Budd, G.T., Ellis, M.J., Stopeck, A., Reuben, J.M. et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol23: 1420-1430.
14.
Danila, D.C., Heller, G., Gignac, G.A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E. et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res13: 7053-7058.
15.
de Bono, J.S., Attard, G., Adjei, A., Pollak, M.N., Fong, P.C., Haluska, P. et al. (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res13: 3611-3616.
16.
de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H. et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res14: 6302-6309.
17.
De Giorgi, U., Valero, V., Rohren, E., Dawood, S., Ueno, N.T., Miller, M.C. et al. (2009) Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol27: 3303-3311.
18.
Desar, I.M., van Herpen, C.M., van Laarhoven, H.W., Barentsz, J.O., Oyen, W.J., van der. and Graaf, W.T. ( 2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev35: 309-321.
Fehm, T., Becker, S., Duerr-Stoerzer, S., Sotlar, K., Mueller, V., Wallwiener, D. et al. (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res9: R74.
21.
Fidler, I.J. ( 1970) Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2’-deoxyuridine. J Natl Cancer Inst45: 773-782.
22.
Fidler, I.J. ( 2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer3: 453-458.
23.
Fidler, I.J. and Poste, G. ( 2008) The ‘‘seed and soil’’ hypothesis revisited. Lancet Oncol9: 808.
24.
Friedl, P. and Gilmour, D.(2009) Collective cell migration in morphogenesis, regeneration and cancer . Nat Rev Mol Cell Biol10: 445-457.
25.
Hayes, D.F., Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Miller, M.C. et al. (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res12: 4218-4224.
26.
Hayes, D.F., Walker, T.M., Singh, B., Vitetta, E.S., Uhr, J.W., Gross, S. et al. (2002) Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol21: 1111-1117.
27.
Hou, J.M., Greystoke, A., Lancashire, L., Cummings, J., Ward, T., Board, R. et al. (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy . Am J Pathol175: 808-816.
28.
Ilina, O. and Friedl, P.(2009) Mechanisms of collective cell migration at a glance. J Cell Sci122: 3203-3208.
29.
Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M. et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med352: 786-792.
30.
Krebs, M.G., Sloane, R., Priest, L., Lancashire, L., Hou, J.M., Greystoke, A. et al. (2010) Evaluation and prognostic significance of circulating tumor cells in patients with non small cell lung cancer (NSCLC). J Clin Oncol, in press.
31.
Leversha, M.A., Han, J., Asgari, Z., Danila, D.C., Lin, O., Gonzalez-Espinoza, R. et al. (2009) Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res15: 2091-2097.
32.
Liotta, L.A., Saidel, M.G. and Kleinerman, J. ( 1976) The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res36: 889-894.
33.
Liu, M.C., Shields, P.G., Warren, R.D., Cohen, P., Wilkinson, M., Ottaviano, Y.L. et al. (2009) Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol27: 5153-5159.
34.
Maheswaran, S., Sequist, L.V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C.V. et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med359: 366-377.
35.
Mandrekar, S.J., Qi, Y., Hillman, S.L., Allen Ziegler, K.L., Reuter, N.F., Rowland Jr, K.M. et al. (2010) Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol5: 3-9.
36.
Martin, M., Garcia-Saenz, J.A., Maestro de las Casas, M.L., Vidaurreta, M., Puente, J., Veganzones, S. et al. (2009) Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Anticancer Res29: 4185-4187.
37.
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S. et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A101: 9393-9398.
38.
Miller, M.C., Doyle, G.V. and Terstappen, L.W. ( 2010) Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol2010: 617421.
39.
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med361: 947-957.
40.
Moreno, J.G., O’Hara, S.M., Gross, S., Doyle, G., Fritsche, H., Gomella, L.G. et al. (2001) Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology58: 386-392.
41.
Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L. et al. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature450: 1235-1239.
42.
Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N. et al. (2009) Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer [Epub Aug 1 2009 ].
43.
Nguyen, D.X., Bos, P.D. and Massague, J.(2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer9: 274-284.
44.
Nole, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E. et al. (2008) Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications . Ann Oncol19: 891-897.
45.
Olmos, D., Arkenau, H.T., Ang, J.E., Ledaki, I., Attard, G., Carden, C.P. et al. (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience . Ann Oncol20: 27-33.
46.
Paget, S. ( 1889) The distribution of secondary growths in cancer of the breast. Lancet1: 571-573.
47.
Pantel, K., Alix-Panabieres, C. and Riethdorf, S. ( 2009) Cancer micrometastases. Nat Rev Clin Oncol6: 339-351.
48.
Paterlini-Brechot, P. and Benali, N.L. ( 2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett253: 180-204.
49.
Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C. et al. (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat118: 523-530.
50.
Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B. et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res13: 920-928.
51.
Scher, H.I., Jia, X., de Bono, J.S., Fleisher, M., Pienta, K.J., Raghavan, D. et al. (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol10: 233-239.
52.
Sequist, L.V., Bell, D.W., Lynch, T.J. and Haber, D.A. ( 2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol25: 587-595.
53.
Sequist, L.V., Nagrath, S., Toner, M., Haber, D.A. and Lynch, T.J. ( 2009) The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol4: 281-283.
54.
Smirnov, D.A., Zweitzig, D.R., Foulk, B.W., Miller, M.C., Doyle, G.V., Pienta, K.J. et al. (2005) Global gene expression profiling of circulating tumor cells. Cancer Res65: 4993-4997.
55.
Stebbing, J. and Jiao, L.R.(2009) Circulating tumour cells as more than prognostic markers. Lancet Oncol10: 1138-1139.
56.
Swennenhuis, J.F., Tibbe, A.G., Levink, R., Sipkema, R.C. and Terstappen, L.W.(2009) Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A75: 520-527.
57.
Theodoropoulos, P.A., Polioudaki, H., Agelaki, S., Kallergi, G., Saridaki, Z., Mavroudis, D. et al. (2010) Circulating tumor cells with a putative stem cell
58.
phenotype in peripheral blood of patients with breast cancer. Cancer Lett288: 99-106.
59.
Thiery, J.P. ( 2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol15: 740-746.
Tibbe, A.G., Miller, M.C. and Terstappen, L.W. ( 2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A71: 154-162.
62.
Tol, J., Koopman, M., Miller, M.C., Tibbe, A., Cats, A., Creemers, G.J. et al. (2010) Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol21: 1006-1012.
63.
Tsuji, T., Ibaragi, S. and Hu, G.F.(2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis . Cancer Res69: 7135-7139.
64.
Weiss, L. ( 2000) Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev19(I-XI): 193-383.
65.
Wittekind, C. and Neid, M. ( 2005) Cancer invasion and metastasis. Oncology69(Suppl 1): 14-16.
66.
Yang, J., Mani, S.A. and Weinberg, R.A. ( 2006) Exploring a new twist on tumor metastasis. Cancer Res66: 4549-4552.
